June 30, 2021 -- Cenexi signed a deal agreeing to manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' COVID-19 vaccine candidate, which will be used in the product's development phases.
Under the deal, Cenexi will make and process the peptides, produce the sterile emulsion, and package clinical batches of the vaccine that is being used in the ongoing phase I clinical trial. The next-generation candidate is a multitarget, multivariant vaccine. The manufacturing will occur at Cenexi's site in Hérouville-Saint-Clair in Normandy, France. The site has a filling capacity of 40 million bottles annually.
Financial details of the agreement were not disclosed.